Quarterly ResultAug 13, 2026, 08:13 AM
CorMedix Q2 Revenue $101.9M, Net Income $26.0M; H1 Revenue $229.4M
AI Summary
CorMedix Inc. reported strong financial results for the second quarter and first half of 2026, significantly boosted by the acquisition of Melinta Therapeutics in August 2025. For the three months ended June 30, 2026, total revenue and grant income reached $101.9 million, leading to a net income of $26.0 million. For the six months ended June 30, 2026, total revenue and grant income was $229.4 million, with net income at $64.6 million. The company also noted a $10.9 million expense from the change in fair value of contingent consideration for the first half of 2026.
Key Highlights
- Q2 2026 Total Revenue and Grant Income: $101.9 million, up from $39.7 million YoY.
- Q2 2026 Net Income: $26.0 million, up from $19.8 million YoY.
- H1 2026 Total Revenue and Grant Income: $229.4 million, up from $78.8 million YoY.
- H1 2026 Net Income: $64.6 million, up from $40.5 million YoY.
- H1 2026 Diluted EPS: $0.72, up from $0.58 YoY.
- Cash and cash equivalents: $256.7 million as of June 30, 2026.
- Total Stockholders' Equity: $460.8 million as of June 30, 2026.
- Change in contingent consideration: $10.9 million expense for H1 2026.
Price Impact
More from CRMD